GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2009

FDA Clears Transgenically Produced Therapeutic

  • The FDA gave the green light to the first ever transgenically produced therapeutic protein, also the first recombinant antithrombin, according to the drug's manufacturer, GTC Biotherapeutics, and its partner, Ovation Pharmaceuticals. The companies expect ATryn® to be available in the second quarter.

    ATryn® (Antithrombin [Recombinant]) was approved for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients. It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.

    In June, the two firms entered into a collaboration agreement to develop and market ATryn in the U.S. The agreement included $257 million in potential payments to GTC for meeting clinical, regulatory, and sales milestones. 

    Along with the approval of ATryn, the FDA’s Center for Veterinary Medicine also approved GTC’s New Animal Drug Application, the first of its kind to regulate genetically engineered animals. This is now required for a recombinant technology used to develop transgenic animals, such as the goats that produce recombinant antithrombin, the company reports.

    “The approval of ATryn marks a significant milestone in the development of this innovative recombinant technology and delivers a new therapeutic option to benefit hereditary antithrombin deficient patients who are undergoing surgery or childbirth procedures,” said Geoffrey F. Cox, Ph.D., GTC’s chairman and CEO.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?